case_images: PMC9040448_01
case_images: PMC9040448_02
case_images: A 36-year-old man with pemphigus vulgaris. (A) Confluent erosions with purulent crusts on the scalp in February 2021. (B) Improvement of the lesions 9 months after rituximab treatment.
case_images: fmed-08-811562-g0001.jpg
case_images: PMC9040448_02_fmed-08-811562-g0001.jpg
case_images: F1
case_images: Once the PV activity persisted and his comorbidities such as diabetes and obesity aggravated, we decided for rituximab (RTX), two 1 g infusions, administered on January 18 and February 5, 2021 (Figure 1A). On October 25, 2021, during his last follow-up visit, PV was on remission with prednisone 7.5 mg/day (Figure 1B).
case_images: PMC9040448_03
case_images: PMC9040448_04
case_images: A 61-year-old man with pemphigus vulgaris had a recurrence of the disease after withdrawn of mycophenolate mofetil in November 2021 and presented (A) eroded plaques with purulent crusts and keratotic areas on the trunk in July 2021. Lesions were recalcitrant to prednisone 1 mg/kg/d and mycophenolate mofetil 3 g/d, and only improved 1 month after 2 rituximab infusions (B).
case_images: fmed-08-811562-g0002.jpg
case_images: PMC9040448_04_fmed-08-811562-g0002.jpg
case_images: F2
case_images: Secondary bacterial infection required prolonged treatment with trimethoprim/sulfamethoxazole 160/800 mg BID (Figure 2A). The patient received the additional COVID immunization, had no adverse effects and currently presents partial PV control on therapy Prednisone (30 mg/d) after 9 weeks of rituximab therapy (Figure 2B).